HR and breast cancer: In line with our findings, retrospective studies and several phase II single-agent clinical trials have consistently shown the benefit of switching ET and continuing CDK4/6 therapy in patients with HR+/HER2- metastatic BC whose disease has progressed on prior hormonal therapy and a CDK4/6i.